Refractory Hematologic Malignancies Article Swipe

View

Mark A. Dawson , Brian J.P. Huntly , Adrián Alegre , Daniel A. Pollyea , Faith E. Davies , Gareth J. Morgan , Manali Kamdar , Ludovica Marando , Evi Bakirtzi , Natalie O. Karpinich , Michael T. McCabe , Shawn W. Foley ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1158/1078-0432.30707609

Supplementary Methods

Related Topics

Gayniggers From Outer Space

Data

From Hilde, With Love

Quotations From Chairman Mao Tse-Tung

Data Mining

Far From The Madding Crowd (2015 Film)

Dancer From The Dance

Polity Data Series

Concepts

No concepts available.

Metadata

Type: article
Landing Page: https://doi.org/10.1158/1078-0432.30707609
OA Status: gold
OpenAlex ID: https://openalex.org/W4416671596

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4416671596

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1078-0432.30707609

Digital Object Identifier
Title: Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

Work title
Type: article

OpenAlex work type
Publication year: 2025

Year of publication
Publication date: 2025-11-25

Full publication date if available
Authors: Mark A. Dawson, Brian J.P. Huntly, Adrián Alegre, Daniel A. Pollyea, Faith E. Davies, Gareth J. Morgan, Manali Kamdar, Ludovica Marando, Evi Bakirtzi, Natalie O. Karpinich, Michael T. McCabe, Shawn W. Foley

List of authors in order
Landing page: https://doi.org/10.1158/1078-0432.30707609

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/1078-0432.30707609

Direct OA link when available
Cited by: 0

Total citation count in OpenAlex

Full payload

id	https://openalex.org/W4416671596
doi	https://doi.org/10.1158/1078-0432.30707609
ids.doi	https://doi.org/10.1158/1078-0432.30707609
ids.openalex	https://openalex.org/W4416671596
fwci	0.0
type	article
title	Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
is_xpac	False
apc_list
apc_paid
language
locations[0].id	doi:10.1158/1078-0432.30707609
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1078-0432.30707609
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5058771300
authorships[0].author.orcid	https://orcid.org/0000-0002-5464-5029
authorships[0].author.display_name	Mark A. Dawson
authorships[0].author_position	first
authorships[0].raw_author_name	Mark A. Dawson
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5029251605
authorships[1].author.orcid	https://orcid.org/0000-0003-0312-161X
authorships[1].author.display_name	Brian J.P. Huntly
authorships[1].author_position	middle
authorships[1].raw_author_name	Brian J.P. Huntly
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5034430204
authorships[2].author.orcid	https://orcid.org/0000-0002-2423-822X
authorships[2].author.display_name	Adrián Alegre
authorships[2].author_position	middle
authorships[2].raw_author_name	Adrian Alegre
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5032549755
authorships[3].author.orcid	https://orcid.org/0000-0001-6519-4860
authorships[3].author.display_name	Daniel A. Pollyea
authorships[3].author_position	middle
authorships[3].raw_author_name	Daniel A. Pollyea
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5034560778
authorships[4].author.orcid	https://orcid.org/0000-0002-3971-2393
authorships[4].author.display_name	Faith E. Davies
authorships[4].author_position	middle
authorships[4].raw_author_name	Faith E. Davies
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5100632493
authorships[5].author.orcid	https://orcid.org/0000-0002-4271-6360
authorships[5].author.display_name	Gareth J. Morgan
authorships[5].author_position	middle
authorships[5].raw_author_name	Gareth J. Morgan
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5000537427
authorships[6].author.orcid	https://orcid.org/0000-0002-1930-152X
authorships[6].author.display_name	Manali Kamdar
authorships[6].author_position	last
authorships[6].raw_author_name	Manali Kamdar
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5025868115
authorships[7].author.orcid	https://orcid.org/0000-0002-6154-850X
authorships[7].author.display_name	Ludovica Marando
authorships[7].author_position	middle
authorships[7].raw_author_name	Ludovica Marando
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5011399103
authorships[8].author.orcid
authorships[8].author.display_name	Evi Bakirtzi
authorships[8].author_position	middle
authorships[8].raw_author_name	Evi Bakirtzi
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5055882272
authorships[9].author.orcid
authorships[9].author.display_name	Natalie O. Karpinich
authorships[9].author_position	middle
authorships[9].raw_author_name	Natalie O. Karpinich
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5039169226
authorships[10].author.orcid	https://orcid.org/0000-0001-5715-9563
authorships[10].author.display_name	Michael T. McCabe
authorships[10].author_position	middle
authorships[10].raw_author_name	Michael T. McCabe
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5043486929
authorships[11].author.orcid
authorships[11].author.display_name	Shawn W. Foley
authorships[11].author_position	middle
authorships[11].raw_author_name	Shawn W. Foley
authorships[11].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.1158/1078-0432.30707609
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-11-25T00:00:00
display_name	Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
has_fulltext	False
is_retracted	False
updated_date	2025-11-28T20:16:53.979499
primary_topic
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/1078-0432.30707609
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1078-0432.30707609
primary_location.id	doi:10.1158/1078-0432.30707609
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1078-0432.30707609
publication_date	2025-11-25
publication_year	2025
referenced_works_count	0
abstract_inverted_index.Methods</p>	1
abstract_inverted_index.<p>Supplementary	0
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	12
citation_normalized_percentile